Biohaven (BHVN) is down -10.9%, or -$3.02 to $24.62.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Immunovant data positive for Biohaven, says Deutsche Bank
- Positive Outlook for Biohaven Ltd. Amid Promising Developments and FDA Priority Review
- Biotech Alert: Searches spiking for these stocks today
- Optimistic Buy Rating for Biohaven Ltd. Amid Promising Drug Developments and Strategic Pipeline Advancements
- Biohaven price target lowered to $63 from $69 at Morgan Stanley